TARO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	26 688.00
Gjennomsnittsvolum	43 979.00
Markedsverdi	1.59B
EPS	$0 ( 2024-01-25 )
Neste inntjeningsdato	( $0.310 ) 2024-05-28
Last Dividend	$12.81 ( 2018-12-10 )
Next Dividend	$0 ( N/A )
P/E	34.75
ATR14	$0.0200 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2011-01-18	Sun Pharmaceutical Industries Ltd	Buy	712 500	Restricted Shares
2011-01-18	Sun Pharmaceutical Industries Ltd	Buy	712 500	Restricted Shares
2011-01-18	Sun Pharmaceutical Industries Ltd	Sell	712 500	Warrant (right to buy)
2010-11-04	Sun Pharmaceutical Industries Ltd	Buy	5 159 765	Ordinary Shares
2010-11-01	Franklin Resources Inc	Sell	5 159 765	Ordinary Shares

INSIDER POWER
0.00
Last 84 transactions
Buy: 16 575 249 \| Sell: 25 681 902

Volum Korrelasjon

Lang: 0.07 (neutral)

Kort: -0.73 (moderate negative)

Signal:(41.437) Neutral

Taro Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Taro Pharmaceutical Korrelasjon - Valuta/Råvare

0.69
( moderate )

0.47
( neutral )

0.00
( neutral )

0.49
( neutral )

0.18
( neutral )

0.84
( strong )

Taro Pharmaceutical Økonomi

Annual	2023
Omsetning:	$572.95M
Bruttogevinst:	$268.32M (46.83 %)
EPS:	$0.680

FY	2023
Omsetning:	$572.95M
Bruttogevinst:	$268.32M (46.83 %)
EPS:	$0.680

FY	2022
Omsetning:	$561.35M
Bruttogevinst:	$293.12M (52.22 %)
EPS:	$1.550

FY	2021
Omsetning:	$548.97M
Bruttogevinst:	$296.66M (54.04 %)
EPS:	$-10.12

Financial Reports:

No articles found.

Taro Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Taro Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.86 - average (62.51%) | Divividend Growth Potential Score: 2.19 - No dividend growth expected in the near future

Information

First Dividend	$12.81	2018-12-10
Last Dividend	$12.81	2018-12-10
Next Dividend	$0	N/A
Payout Date	2018-12-28
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$12.81	--
Avg. Dividend % Per Year	0.00%	--
Score	1.22	--
Div. Sustainability Score	5.86
Div.Growth Potential Score	2.19
Div. Directional Score	4.03	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.22

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2018	$12.81	12.40%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0748	1.500	8.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0211	1.200	9.30	10.00	[0 - 0.3]
returnOnEquityTTM	0.0261	1.500	-0.821	-1.231	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.60	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.03	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.022	1.500	5.43	8.15	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-2.55	1.000	-2.05	-2.05	[3 - 30]
operatingCashFlowPerShareTTM	3.80	2.00	8.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.29	2.00	8.86	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.480	1.000	5.33	5.33	[0.2 - 0.8]
operatingProfitMarginTTM	0.0360	1.000	-1.280	-1.280	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.282	0.800	-1.451	-1.161	[0.5 - 2]
Total Score				5.86

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	34.87	1.000	6.58	0	[1 - 100]
returnOnEquityTTM	0.0261	2.50	-0.528	-1.231	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.29	2.00	9.24	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.80	2.00	8.73	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.769	1.500	-8.46	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.234	1.000	6.65	0	[0.1 - 0.5]
Total Score				2.19

Taro Pharmaceutical

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.